文献速递基础与转化研究临床试验与 GCP

CD4+ CAR T细胞强劲扩增与多发性骨髓瘤患者西达基奥仑赛后的非ICANS神经毒性相关

Robust CD4+ CAR T cell expansion is associated with non-ICANS neurotoxicities after ciltacabtagene autoleucel in patients with multiple myeloma.
PubMed 文献 · Sci Transl Med · 2026-07-29

该研究纳入109例接受西达基奥仑赛治疗的复发/难治多发性骨髓瘤患者,发现高绝对淋巴细胞计数峰值是非ICANS神经毒性的强预测因子,且与流式检测的外周血CAR T细胞数量直接相关;观察到的CAR淋巴细胞增多为多克隆并偏向CD4+ CAR T细胞,富含记忆标志物,并鉴定出与神经毒性相关的CD4+ CAR T细胞群。

要点

  • 高绝对淋巴细胞计数峰值可预测非ICANS神经毒性。
  • 外周血CAR T细胞定量与淋巴细胞峰值直接相关。
  • CD4+ CAR T细胞扩增与炎症通路基因表达增加相关。

核心结论

  • 高绝对淋巴细胞计数峰值是非ICANS神经毒性的强预测因子,与CD4+ CAR T细胞扩增相关。

研究设计与样本

  • 队列研究,纳入109例接受西达基奥仑赛治疗的复发/难治多发性骨髓瘤患者。

主要发现

  • 高绝对淋巴细胞计数峰值与非ICANS神经毒性强相关。
  • CAR淋巴细胞增多为多克隆,偏向CD4+ CAR T细胞且富含记忆标志物。
  • 鉴定出与神经毒性相关的CD4+ CAR T细胞群,其炎症通路基因表达增加。

临床怎么用

  • 监测绝对淋巴细胞计数峰值和CAR T细胞扩增可能有助于识别非ICANS神经毒性高风险患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Nonimmune effector cell-associated neurotoxicity syndrome neurotoxicities (NINTs) are serious, atypical toxicities associated with ciltacabtagene autoleucel (cilta-cel), a US Food and Drug Administration chimeric antigen receptor T cell (CAR T cell) therapy approved for relapsed/refractory multiple myeloma (RRMM). Risk factors contributing to the development of NINTs are poorly understood. In a cohort of 109 patients with RRMM treated with cilta-cel, we identify predisposing risk factors and propose strategies to mitigate NINTs. We show that high-peak absolute lymphocyte count is a strong NINT predictor, which directly correlates with flow cytometry-based peripheral blood CAR T cell quantitation. The observed CAR lymphocytosis was polyclonal with a bias toward CD4+ CAR T cells rich in memory marker expression. We then identified CAR lymphocytosis-associated CD4+ CAR T cell populations, which exhibited increased inflammatory pathway gene expression. Last, we characterize NINT-associated CD4+ CAR T cell populations, which are potential therapeutic targets for future exploration.

来源:Sci Transl Med,查看原文。版权归原作者所有。

引用

  1. Jurgens EM, Mitra S, Herrera K, et al. Robust CD4+ CAR T cell expansion is associated with non-ICANS neurotoxicities after ciltacabtagene autoleucel in patients with multiple myeloma. Sci Transl Med. 2026. PMID: 42525783. doi:10.1126/scitranslmed.aed0039

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。